MyMD Pharmaceuticals (MYMD) Competitors $0.10 0.00 (-2.57%) As of 08/14/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsInsider TradesOptions ChainSEC FilingsTrendsBuy This Stock MYMD vs. PTPI, SRNE, ZVSA, PBLA, BPTSY, HEPA, VIRX, VINC, NCNA, and TRVNShould you be buying MyMD Pharmaceuticals stock or one of its competitors? The main competitors of MyMD Pharmaceuticals include Petros Pharmaceuticals (PTPI), Sorrento Therapeutics (SRNE), ZyVersa Therapeutics (ZVSA), Panbela Therapeutics (PBLA), Biophytis (BPTSY), Hepion Pharmaceuticals (HEPA), Viracta Therapeutics (VIRX), Vincerx Pharma (VINC), NuCana (NCNA), and Trevena (TRVN). These companies are all part of the "pharmaceutical products" industry. MyMD Pharmaceuticals vs. Its Competitors Petros Pharmaceuticals Sorrento Therapeutics ZyVersa Therapeutics Panbela Therapeutics Biophytis Hepion Pharmaceuticals Viracta Therapeutics Vincerx Pharma NuCana Trevena MyMD Pharmaceuticals (NASDAQ:MYMD) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment. Do institutionals and insiders have more ownership in MYMD or PTPI? 9.6% of MyMD Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by institutional investors. 2.1% of MyMD Pharmaceuticals shares are owned by insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has preferable valuation and earnings, MYMD or PTPI? MyMD Pharmaceuticals has higher earnings, but lower revenue than Petros Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMyMD PharmaceuticalsN/AN/A-$4MN/AN/APetros Pharmaceuticals$5.11M0.19-$8.16M-$60.870.00 Which has more volatility & risk, MYMD or PTPI? MyMD Pharmaceuticals has a beta of 2.15, suggesting that its share price is 115% more volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Is MYMD or PTPI more profitable? Petros Pharmaceuticals' return on equity of -78.22% beat MyMD Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets MyMD PharmaceuticalsN/A -179.05% -108.14% Petros Pharmaceuticals N/A -78.22%-23.50% Does the media prefer MYMD or PTPI? In the previous week, Petros Pharmaceuticals had 1 more articles in the media than MyMD Pharmaceuticals. MarketBeat recorded 1 mentions for Petros Pharmaceuticals and 0 mentions for MyMD Pharmaceuticals. MyMD Pharmaceuticals' average media sentiment score of 0.00 equaled Petros Pharmaceuticals'average media sentiment score. Company Overall Sentiment MyMD Pharmaceuticals Neutral Petros Pharmaceuticals Neutral SummaryPetros Pharmaceuticals beats MyMD Pharmaceuticals on 6 of the 8 factors compared between the two stocks. Get MyMD Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MYMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MYMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYMD vs. The Competition Export to ExcelMetricMyMD PharmaceuticalsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$242K$18.44M$5.66B$9.82BDividend YieldN/AN/A3.79%4.07%P/E RatioN/AN/A30.5825.12Price / SalesN/A20.56462.42114.82Price / CashN/AN/A37.4059.05Price / Book0.010.019.096.18Net Income-$4M-$15.34M$3.25B$264.89M7 Day PerformanceN/A8.24%7.32%4.18%1 Month Performance-3.67%-2.20%5.41%1.99%1 Year Performance-94.32%-38.96%30.66%24.22% MyMD Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYMDMyMD PharmaceuticalsN/A$0.10-2.6%N/A-94.3%$242KN/A0.006Gap DownHigh Trading VolumePTPIPetros Pharmaceuticals0.2369 of 5 stars$0.03-2.1%N/A-99.6%$885K$5.11M-0.0120Gap DownSRNESorrento Therapeutics0.8421 of 5 stars$0.00-34.8%N/A-79.0%$827K$60.32M0.00800Gap DownZVSAZyVersa Therapeutics0.7157 of 5 stars$0.16-2.5%N/A-94.9%$780KN/A0.002News CoverageGap DownPBLAPanbela Therapeutics1.1224 of 5 stars$0.16-7.1%N/A-57.3%$767KN/A0.006Short Interest ↓Gap DownBPTSYBiophytisN/A$1.81flatN/A-67.2%$634KN/A0.0030Short Interest ↓HEPAHepion Pharmaceuticals0.9261 of 5 stars$0.05+16.2%N/A-99.8%$533KN/A-0.0120News CoverageShort Interest ↓Gap UpVIRXViracta Therapeutics1.7702 of 5 stars$0.01flat$1.75+17,793.7%N/A$389KN/A-0.0120Negative NewsVINCVincerx Pharma2.7277 of 5 stars$0.07+91.7%$40.00+61,438.5%-99.7%$340KN/A0.0060NCNANuCana3.5404 of 5 stars$0.04-4.7%$25.00+61,628.4%-99.4%$246KN/A-0.0130Upcoming EarningsAnalyst UpgradeShort Interest ↓TRVNTrevena1.1514 of 5 stars$0.25-72.5%$5.00+1,900.0%-92.6%$240K$443K-0.0140Short Interest ↑Gap Down Related Companies and Tools Related Companies PTPI Alternatives SRNE Alternatives ZVSA Alternatives PBLA Alternatives BPTSY Alternatives HEPA Alternatives VIRX Alternatives VINC Alternatives NCNA Alternatives TRVN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MYMD) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MyMD Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MyMD Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access